



CompuGroup Medical

Quarterly Report as of March 31, 2023

Synchronizing Healthcare.
Creating the future of e-health.

Q1/2023 AT A GLANCE

Group revenues at mEUR 291, up 16 % compared to prior year quarter

Organic revenue growth at 10.5 % (prior year quarter: 5.4 %)

Adjusted EBITDA at mEUR 60, up 16 % compared to prior year quarter

Adjusted EBITDA margin of 21 % (prior year quarter: 20 %)

Adjusted EPS at 0.45 EUR (prior year quarter: 0.41 EUR)

Free cash flow of mEUR 79 (prior year quarter: mEUR 65)

Financial key figures

| kEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 | Change |
|-------------------------------------|-----------------------|-----------------------|-----------|
| Revenues | 290,843 | 251,649 | + 16 % |
| Recurring revenues in % | 68 % | 71 % | - 3 ppt |
| Organic growth in % | 10.5 % | 5.4 % | + 5.1 ppt |
| EBITDA adjusted | 59,949 | 51,516 | + 16 % |
| EBITDA margin adjusted | 20.6 % | 20.5 % | + 0.1 ppt |
| EPS adjusted (EUR) - diluted | 0.45 | 0.41 | + 8 % |
| Free cash flow | 78,503 | 64,609 | + 22 % |
| Number of shares outstanding ('000) | 52,235 | 52,235 | - 0 % |

NOTICE

CompuGroup Medical has been reporting adjusted key figures for the operating result (EBITDA) and earnings per share since the financial year 2020. These key figures are not defined under International Financial Reporting Standards (IFRS) and should be regarded as supplementary information. Adjusted EBITDA and adjusted earnings per share exclude effects from major acquisition and disposal of subsidiaries, business units and investments (including effects from the subsequent measurement of contingent purchase price liabilities), impairment losses and write-ups on investments, effects from the acquisition, construction and disposal of real estate, impairment losses and write-ups on owner-occupied property, as well as expenses in connection with share-based payment programs for Managing Directors, taxes attributable to the above effects and other non-operating or non-periodic non-recurring effects.

Unless otherwise stated, all information and explanatory notes in this report refer to the first quarter of 2023 and 2022, i.e. the three-month period from January 1 to March 31 (Q1), and all percentage changes refer to the respective year-on-year comparison. Due to rounding, totals and percentages presented in this report may not add up precisely to the totals provided.

EARNINGS DEVELOPMENT IN THE GROUP

| kEUR | 01.01.-31.03.2023 | 01.01.-31.03.2022 |
|---|-------------------|-------------------|
| Revenues | 290,843 | 251,649 |
| Other income | 1,275 | 1,115 |
| Capitalized in-house services | 10,575 | 10,872 |
| Expenses for goods and services purchased | -54,655 | -39,862 |
| Personnel expenses | -135,550 | -133,111 |
| Other expenses | -53,789 | -44,082 |
| EBITDA | 58,699 | 46,581 |
| in % of revenues | 20.2% | 18.5% |
| EBIT | 32,383 | 19,365 |
| in % of revenues | 11.1% | 7.7% |
| EBT | 20,884 | 26,260 |
| in % of revenues | 7.2% | 10.4% |
| Consolidated net income | 14,491 | 18,241 |
| in % of revenues | 5.0% | 7.2% |

Revenue increased by mEUR 39 (+ 16 %) to mEUR 291 for the first quarter of 2023. Organic growth in this period was 10.5 % year-on-year.

Adjusted earnings before interest, taxes, depreciation and amortization (adjusted group EBITDA) amounted to mEUR 60 (previous year: mEUR 52) with an adjusted EBITDA margin of 20.6 % (prior year: 20.5 %).

Adjusted group EBITDA was derived from reported EBITDA as shown below:

| kEUR | 01.01.-31.03.2023 | 01.01.-31.03.2022 |
|--|-------------------|-------------------|
| EBITDA reported | 58,699 | 46,581 |
| Adjustments: | | |
| M&A transactions | 646 | 1,385 |
| Share-based option programs | 604 | 1,621 |
| Restructuring program expenses | 0 | 0 |
| Other non-operative, extraordinary or one-time effects | 0 | 1,929 |
| EBITDA adjusted | 59,949 | 51,516 |
| Adjusted EBITDA margin in % | 20.6 % | 20.5 % |

At group level, the main developments in operating expenses in the first quarter of the financial year 2023 can be described as follows:

- The expenses for goods and services purchased increased from mEUR 40 to mEUR 55 compared to the reference period of last year. The gross margin (revenues less cost of purchased services/revenues) of 81 % is 3 percentage points lower as in the previous year.
- The increase in personnel expenses from mEUR 133 in 2022 to mEUR 136 in 2023 is due to acquisitions.
- Other expenses including impairment losses on financial assets and contract assets increased from mEUR 44 in 2022 to mEUR 54 in 2023, mainly due to additional expenses for major projects as well as increased costs of software maintenance and travel expenses.

Depreciation of property, plant and equipment and right-of-use assets amounted to mEUR 10 in the first quarter of 2023, the same level as prior year (mEUR 10). Amortization of intangible assets decreased by mEUR 1 to mEUR 16 in the same period.

Amortization of intangible assets consists of the following:

| kEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 |
|---|-----------------------|-----------------------|
| Amortization of intangible assets | 16,384 | 17,556 |
| thereof from purchase price allocations for business combinations | 10,909 | 11,280 |
| thereof from capitalized inhouse services | 3,475 | 2,369 |

The financial result was structured as follows:

| kEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 |
|--|-----------------------|-----------------------|
| Interest and other expenses on loans and financial services | - 5,758 | - 2,250 |
| Changes in purchase price liabilities | - 75 | - 830 |
| Capitalized interest on qualifying assets under construction (IAS 23) | 555 | 200 |
| Interest income on loans | 64 | 84 |
| Interest income on cash at bank | 96 | 39 |
| Currency losses / gains | - 2,136 | 1,325 |
| Write-down/Write-up of derivatives without hedge accounting relationship | - 4,301 | 8,695 |
| Other | 56 | - 368 |
| TOTAL | - 11,499 | 6,895 |

In the first quarter of 2023, consolidated net income amounted to mEUR 14 and was thus mEUR 4 lower than in the prior year period. The Group's tax rate for the first quarter was unchanged at 31 % compared to the first quarter of the previous year.

Adjusted earnings per share were as follows:

| kEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 |
|--|-----------------------|-----------------------|
| Consolidated net income for the period | 14,491 | 18,241 |
| of which: allocated to non-controlling interests | - 111 | - 32 |
| Consolidated net income of the period (allocated to shareholders of the parent company) | 14,380 | 18,209 |
| Adjustments: | | |
| M&A transactions | 6,891 | 7,916 |
| Share-based option programs | 604 | 1,621 |
| Restructuring program expenses | 0 | 0 |
| Other non-operative, extraordinary or one-time effects | 4,202 | - 6,766 |
| Taxes attributable to these effects | - 2,574 | 697 |
| Adjusted consolidated net income for the period (allocated to shareholders of the parent company) | 23,503 | 21,677 |
| Adjusted undiluted earnings per share (in EUR) | 0.45 | 0.41 |
| Adjusted diluted earnings per share (in EUR) | 0.45 | 0.41 |
| weighted average of outstanding shares acc. to IAS 33 - undiluted ('000) | 52,235 | 52,239 |
| weighted average of outstanding shares acc. to IAS 33 - diluted ('000) | 52,255 | 52,239 |

EARNINGS DEVELOPMENT OF THE BUSINESS SEGMENTS

Ambulatory Information Systems (AIS)

| mEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022* | Change |
|-----------------------------|-----------------------|------------------------|---------|
| Revenues to third parties | 124.8 | 119.7 | + 4 % |
| Share of recurring revenues | 79 % | 78 % | + 1 ppt |
| EBITDA adjusted | 29.4 | 26.3 | + 12 % |
| in % of revenues | 24 % | 22 % | + 2 ppt |

* In 2023, some minor profit centers were reallocated between the AIS and CHS segments, therefore the prior year figures have been updated based on the current structure.

- Revenues in the first quarter 2023 increased to mEUR 125, up 4 % compared to the prior year quarter, supported by acquisition and currency effects. Organically, revenues increased by 2 % compared to the prior year quarter, in particular due to a good business performance in the United States and the continued rollout of e-billing modules in the German dental sector. Recurring revenues in the AIS segment increased by 5 %. At the same time, adjusted EBITDA increased by 12 % to mEUR 29.

Hospital Information Systems (HIS)

| mEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 | Change |
|-----------------------------|-----------------------|-----------------------|---------|
| Revenues to third parties | 73.1 | 66.6 | + 10 % |
| Share of recurring revenues | 70 % | 70 % | + 0 ppt |
| EBITDA adjusted | 3.5 | 5.8 | - 40 % |
| in % of revenues | 5 % | 9 % | - 4 ppt |

- In the first quarter of 2023, revenues increased by 10 % to mEUR 73. Organically, revenues increased by 11 % compared to the first quarter of last year due to strong project business in Germany, Spain and Poland. Recurring revenues increased by 9 % to mEUR 51, representing 70 % of total revenues (prior year quarter: 70 %). Adjusted EBITDA of mEUR 4 was below the prior year due to continued high investments into G3 technology and additional expenses for major projects.

Consumer and Health Management Information Systems (CHS)

| mEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022* | Change |
|-----------------------------|-----------------------|------------------------|---------|
| Revenues to third parties | 57.9 | 35.5 | + 63 % |
| Share of recurring revenues | 46 % | 47 % | - 1 ppt |
| EBITDA adjusted | 14.5 | 9.3 | + 56 % |
| in % of revenues | 25 % | 26 % | - 1 ppt |

* In 2023, some minor profit centers were reallocated between the AIS and CHS segments, therefore the prior year figures have been updated based on the current structure.

- Revenues in the first quarter increased by 63 % to mEUR 58 compared to the prior year quarter, supported by the acquisition effect from INSIGHT Health. Organic growth was also strong (+37 %) due to the continued replacement of hardware connectors in Telematics Infrastructure. Organically and excluding Telematics Infrastructure, the revenue development was impacted by macroeconomic effects on the pharmaceutical industry and increased slightly year-on-year (+ 1 %). Recurring revenues amounted to mEUR 26 and represent 46 % of total CHS revenues (prior year: 47 %). Adjusted EBITDA amounted to mEUR 14 and was thus mEUR 5 higher than in the prior year.

Pharmacy Information Systems (PCS)

| mEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 | Change |
|-----------------------------|-----------------------|-----------------------|---------|
| Revenues to third parties | 35.0 | 29.9 | + 17 % |
| Share of recurring revenues | 66 % | 70 % | - 4 ppt |
| EBITDA adjusted | 11.9 | 7.6 | + 56 % |
| in % of revenues | 34 % | 26 % | + 8 ppt |

- Revenues in the first quarter increased to mEUR 35, up 17 % on the prior year, positively influenced by an acquisition in Italy. Organically, the PCS segment achieved growth of 11 %, in particular due to a strong performance in hardware sales in Italy. Recurring revenues increased by 11 % to mEUR 23, representing 66 % of total revenues (prior year: 70 %). Adjusted EBITDA amounted to mEUR 12 and was thus 56 % above the prior year figure.

Other segments and consolidation

| mEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 | Change |
|---------------------------|-----------------------|-----------------------|--------|
| Revenues to third parties | 0.0 | 0.0 | n/a |
| EBITDA adjusted | 0.6 | 2.5 | - 77 % |

- Adjusted EBITDA in the first quarter was mEUR 2 lower than in the reference period of last year. Adjusted special items amounted to mEUR 1 in the first quarter and were attributable to stock option programs.

Staff development

| Staff Development | Mar 31, 2023 | Mar 31, 2022 | Dec 31, 2022 |
|---|--------------|--------------|--------------|
| Number of employees (HC) | 9,193 | 8,856* | 9,229 |
| thereof from acquisitions as at time of acquisition | 40 | 5 | 231 |
| Full-time equivalent (FTE)** | 8,825 | 8,481* | 8,833 |

* Prior year figure adjusted.

** FTE: Indicates for a number of real jobs with different time models the number of notional full-time jobs with the same work capacity.

The headcount decreased by 36 employees compared to end of 2022. 40 employees joined the Group as part of acquisitions. The number of FTEs decreased by 8 compared with the end of last year.

NET ASSETS OF THE GROUP

| kEUR | Mar 31, 2023 | | Dec 31, 2022 | | Change | |
|---------------------|------------------|--------------|------------------|--------------|-----------------|--------------|
| Non-current assets | 1,532,888 | 79 % | 1,523,631 | 78 % | + 9,257 | + 1 % |
| Current assets | 397,028 | 21 % | 420,807 | 22 % | - 23,779 | - 6 % |
| Total assets | 1,929,916 | 100 % | 1,944,438 | 100 % | - 14,522 | - 1 % |

| kEUR | Mar 31, 2023 | | Dec 31, 2022 | | Change | |
|--------------------------|------------------|--------------|------------------|--------------|-----------------|--------------|
| Equity | 679,984 | 35 % | 673,823 | 35 % | + 6,161 | + 1 % |
| Non-current liabilities | 829,654 | 43 % | 895,141 | 46 % | - 65,487 | - 7 % |
| Current liabilities | 420,278 | 22 % | 375,474 | 19 % | + 44,804 | + 12 % |
| Total Liabilities | 1,929,916 | 100 % | 1,944,438 | 100 % | - 14,522 | - 1 % |

CGM's total assets decreased by mEUR 15 as of March 31, 2023, which corresponds to a decrease from mEUR 1,944 to mEUR 1,930.

The largest changes in assets were as follows:

- Increase in intangible assets by mEUR 17 auf mEUR 1,311 mainly due to acquisitions as well as capitalization of self developed software.
- Decrease in derivative financial instruments by mEUR 6 to mEUR 31, due to the valuation of the interest rate cap and the interest rate swap at quarter end.
- Decrease of cash and cash equivalents by mEUR 25 to mEUR 66, mainly due to repayments of loans.

All other assets were subject to minor changes in absolute figures in first quarter of 2023.

Group equity increased from mEUR 674 as at December 31, 2022 to mEUR 680 as at March 31, 2023. This increase is mainly due to the consolidated net profit for the period, which more than compensates for negative effects related to currency translation and cash flow hedges.

The following significant changes occurred in current and non-current liabilities compared to year-end 2022:

- Decrease in current and non-current liabilities to banks of mEUR 73 to mEUR 656, due to repayments of loans.
- Decrease in trade payables by mEUR 34 to mEUR 78.
- Increase of current and non-current contract liabilities by mEUR 88 to mEUR 170, mainly due to advance payments for software maintenance contracts.

All other current and non-current liabilities were subject to minor changes in absolute figures in the first quarter of 2023.

FINANCIAL POSITION OF THE GROUP

The liquidity situation and financial position of CGM are shown in the following condensed cash flow statement and key figures on debt:

| kEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 | Change |
|--|-----------------------|-----------------------|----------|
| Operating cash flow | 96,119 | 83,831 | 12,288 |
| Cash flow from investing activities | - 41,482 | - 23,339 | - 18,143 |
| Free cash flow | 78,503 | 64,609 | 13,894 |
| Cash flow from financing activities | - 78,658 | - 37,702 | - 40,956 |
| Change in cash and cash equivalents | - 24,021 | 22,790 | - 46,811 |
| Changes due to exchange rate fluctuations | - 887 | 1,229 | - 2,116 |
| Cash and cash equivalents at the beginning of the period | 90,517 | 107,343 | - 16,826 |
| Cash and cash equivalents at the end of the period | 65,609 | 131,362 | - 65,753 |
| Net Debt* | 644,673 | 582,592 | 62,081 |
| Leverage (LTM)** | 2.82 | 2.52 | 0.30 |

* Liabilities to banks (incl. leasing liabilities according to IFRS 16) ./ cash and cash equivalents (with the exception of accounts under third-party management)

** Net debt / EBITDA (LTM) adjusted for restructuring program expenses plus pro rata EBITDA of newly acquired companies

In the first quarter of 2023, free cash flow amounted to mEUR 79 compared to mEUR 65 in the same period of the prior year.

Compared to the same period last year the Free cash flow was significantly higher for Q1 in 2023. The dampening one-off effect from the IT incident during the first month of 2022 was not repeated this year and the working capital has normalized, which has been elevated due to supply chain challenges.

The derivation of free cash flow is shown below:

| kEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 |
|--|-----------------------|-----------------------|
| Operating cash flow | 96,119 | 83,831 |
| Cash flow from investing activities | - 41,482 | - 23,339 |
| ./ Net cash outflow for company acquisitions (less acquired cash and cash equivalents and prepayments in previous periods) | - 21,866 | - 3,517 |
| ./ Cash outflow for acquisitions from prior periods | - 2,000 | 0 |
| ./ Cash inflow from the disposal of subsidiaries and business units | 0 | 0 |
| ./ Cash outflow for capital expenditures in joint ventures and other equity investments | 0 | - 600 |
| Free cash flow | 78,503 | 64,609 |

Cash flow from investing activities amounted to mEUR - 41 in the first quarter of 2023, compared to mEUR - 23 in the same period in prior year.

The derivation of investments is shown below:

| kEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 |
|---|-----------------------|-----------------------|
| Company acquisitions | - 21,866 | - 3,517 |
| Purchase of minority interest and past acquisitions | - 2,000 | 0 |
| Joint ventures and other equity investments | 0 | - 600 |
| CAPEX | - 17,616 | - 19,222 |
| Capitalized in-house services and other intangible assets | - 11,856 | - 11,581 |
| Office buildings and property | - 315 | - 2,502 |
| Other property and equipment | - 5,445 | - 5,139 |
| Total | - 41,482 | - 23,339 |

Cash flow from financing activities amounted to mEUR - 79 in the first quarter of 2023 (prior year: mEUR - 38).

As of March 31, 2023, cash and cash equivalents amounted to MEUR 66 (prior year: mEUR 131). The reported cash and cash equivalents also include restricted cash.

Net debt as at March 31, 2023 was mEUR 645, mEUR 51 lower than the net debt of mEUR 696 as at December 31, 2022. Leverage was 2.82 (December 31, 2022: 3.12) and thus met the requirements of the existing credit agreement.

GUIDANCE

The guidance for the **financial year 2023** remains **unchanged**.

Group

For 2023, CompuGroup Medical SE & Co. KGaA continues to expect:

- An organic revenue growth (adjusted for acquisitions and currency effects) of approximately 5 %
- The share of recurring revenues in total revenues is expected to be between 60 % and 70 %.
- Adjusted EBITDA is expected to range between mEUR 260 and mEUR 300.
- Adjusted earnings per share (diluted) are expected to increase by at least 10 %.
- Free cash flow is expected to be at least mEUR 100.

Segments

The following unchanged performance is expected for the reporting segments in financial year 2023:

- In the AIS segment, organic revenue growth is expected in the mid-single digit percentage range.
- The HIS segment is expected to generate organic revenue growth in the mid to high single digit percentage range.
- In the CHS segment, organic revenue growth is expected in the low to mid-single digit percentage range.
- The PCS segment is expected to generate organic revenue growth in the lower single digit percentage range.

The above guidance for the current financial year does not take into account any effects from company acquisitions not yet completed or potential transactions to be carried out in the course of financial year 2023. The guidance is based on the management's best estimate of future market conditions and the development of the business segments of CompuGroup Medical in this environment; it may be influenced by delays or changes in the implementation of the Telematics Infrastructure that are beyond the control of the company. Moreover, uncertainty remains with regard to the further impact of the global economic environment and the Russia-Ukraine war. The guidance may also be influenced by foreign exchange effects (especially changes in the USD/EUR conversion rate).

Interim Statement of Financial Position

as of March 31, 2023

Assets

| kEUR | Mar 31, 2023 | Mar 31, 2022 | Dec 31, 2022 |
|---|------------------|------------------|------------------|
| Non-current assets | | | |
| Intangible assets | 1,310,989 | 1,220,602 | 1,293,910 |
| Property, plant and equipment | 109,004 | 102,342 | 107,478 |
| Right-of-use assets | 51,419 | 54,209 | 53,411 |
| Investments in associates and joint ventures (valued at-equity) | 7,299 | 6,165 | 7,300 |
| Other investments | 3,157 | 3,127 | 3,158 |
| Finance lease receivables | 14,184 | 16,577 | 15,984 |
| Other financial assets* | 2,016 | 8,872 | 2,111 |
| Derivative financial instruments* | 30,629 | 15,189 | 36,560 |
| Other non-financial assets | 1,200 | 1,200 | 1,200 |
| Deferred taxes | 2,991 | 4,883 | 2,519 |
| | 1,532,888 | 1,433,166 | 1,523,631 |
| Current assets | | | |
| Inventories | 23,931 | 22,994 | 29,438 |
| Trade receivables | 187,646 | 180,014 | 189,439 |
| Finance lease receivables | 7,997 | 8,854 | 9,152 |
| Contract assets | 24,575 | 24,543 | 23,282 |
| Other financial assets | 3,538 | 4,263 | 2,842 |
| Derivative financial instruments | 1,286 | 0 | 574 |
| Other non-financial assets | 36,930 | 32,430 | 27,003 |
| Income tax receivables | 45,516 | 29,588 | 48,560 |
| Cash & cash equivalents | 65,609 | 131,362 | 90,517 |
| | 397,028 | 434,048 | 420,807 |
| | 1,929,916 | 1,867,214 | 1,944,438 |

* Reporting of derivative financial instruments previously under other financial assets.

Interim Statement of Financial Position

as of March 31, 2023

Shareholder's Equity and Liabilities

| kEUR | Mar 31, 2023 | Mar 31, 2022 | Dec 31, 2022 |
|---|------------------|------------------|------------------|
| Equity | | | |
| Subscribed capital | 53,735 | 53,735 | 53,735 |
| Treasury shares | - 105,205 | - 105,205 | - 105,205 |
| Reserves | 729,941 | 681,712 | 723,890 |
| Capital and reserves allocated to the shareholders of the parent company | 678,471 | 630,242 | 672,420 |
| Non-controlling interests | 1,513 | 315 | 1,403 |
| | 679,984 | 630,557 | 673,823 |
| Non-current liabilities | | | |
| Provisions for post-employment benefits and other non-current provisions | 33,081 | 41,441 | 32,656 |
| Liabilities to banks | 629,496 | 531,453 | 699,371 |
| Contract liabilities | 15,135 | 8,607 | 15,529 |
| Purchase price liabilities | 11,746 | 4,340 | 5,539 |
| Lease liabilities | 32,016 | 35,478 | 33,741 |
| Other financial liabilities | 101 | 3,512 | 53 |
| Other non-financial liabilities | 45 | 38 | 42 |
| Deferred taxes | 108,034 | 103,021 | 108,210 |
| | 829,654 | 727,890 | 895,141 |
| Current liabilities | | | |
| Liabilities to banks | 26,152 | 120,643 | 29,104 |
| Contract liabilities | 155,293 | 153,012 | 66,898 |
| Purchase price liabilities | 14,408 | 10,266 | 16,046 |
| Trade payables | 78,310 | 95,628 | 112,613 |
| Income tax liabilities | 24,112 | 12,534 | 32,316 |
| Other provisions | 63,487 | 55,503 | 60,920 |
| Derivative financial instruments | 2,429 | 0 | 901 |
| Lease liabilities | 19,111 | 18,327 | 19,603 |
| Other financial liabilities | 7,128 | 10,105 | 8,478 |
| Other non-financial liabilities | 29,848 | 32,749 | 28,595 |
| | 420,278 | 508,767 | 375,474 |
| | 1,929,916 | 1,867,214 | 1,944,438 |

Interim Income Statement

for the reporting period of January 1 - March 31, 2023

| | 01.01.-31.03.2023 | 01.01.-31.03.2022 | 2022 |
|--|-------------------|-------------------|----------------|
| Revenues | 290,843 | 251,649 | 1,129,739 |
| Capitalized inhouse services | 10,575 | 10,872 | 44,819 |
| Other income | 1,274 | 1,115 | 19,396 |
| Expenses for goods and services purchased | -54,655 | -39,862 | -216,397 |
| Personnel expenses | -135,550 | -133,111 | -546,704 |
| Net impairment losses on financial and contract assets | -3,246 | -270 | -4,961 |
| Other expenses | -50,542 | -43,812 | -209,541 |
| Earnings before interest, taxes, depreciation and amortization (EBITDA) | 58,699 | 46,581 | 216,351 |
| Depreciation of property, plant and equipment and right-of-use assets | -9,932 | -9,660 | -42,770 |
| Earnings before interest, taxes and amortization (EBITA) | 48,767 | 36,921 | 173,581 |
| Amortization of intangible assets | -16,384 | -17,556 | -69,551 |
| thereof from purchase price allocations | -10,909 | -11,280 | -45,882 |
| Earnings before interest and taxes (EBIT) | 32,383 | 19,365 | 104,030 |
| Result from companies accounted for using the equity method | 0 | 0 | -99 |
| Financial income | 252 | 10,150 | 22,719 |
| Financial expenses | -11,751 | -3,255 | -14,584 |
| Net impairment losses on financial assets* | 0 | 0 | -5,250 |
| Earnings before taxes (EBT) | 20,884 | 26,260 | 106,816 |
| Income taxes for the period | -6,393 | -8,018 | -32,699 |
| Consolidated net income for the period | 14,491 | 18,241 | 74,117 |
| of which: allocated to shareholders of the parent company | 14,380 | 18,209 | 73,411 |
| of which: allocated to non-controlling interests | 111 | 32 | 706 |
| Earnings per share | | | |
| undiluted (EUR) | 0.28 | 0.35 | 1.41 |
| diluted (EUR) | 0.28 | 0.35 | 1.40 |

* Reporting of net impairment losses on financial assets previously under financial expenses.

Cash Flow Statement

as of March 31, 2023

| kEUR | 01.01.- 31.03.2023 | 01.01.- 31.03.2022 | 2022 |
|---|-----------------------|-----------------------|-----------------|
| Consolidated net income for the period | 14,491 | 18,241 | 74,117 |
| Depreciation of property, plant and equipment and right-of-use assets and amortization of intangible assets | 26,316 | 27,216 | 112,321 |
| Earnings on sale of fixed assets | 49 | -57 | -163 |
| Change in provisions (including income tax liabilities) | -5,008 | -1,469 | 15,882 |
| Change in derivative financial instruments* | 3,874 | -15,190 | -18,871 |
| Deferred tax income/expense | -32 | 3,201 | 352 |
| Other non-cash earnings/ expenditures | 330 | -1,211 | 4,561 |
| | 40,020 | 30,731 | 188,199 |
| Change in inventories | 5,504 | -2,349 | -8,788 |
| Change in trade receivables and other receivables | 2,647 | -29,663 | -28,761 |
| Change in income tax receivables | 3,057 | 965 | -17,819 |
| Change in other receivables | -10,606 | 116 | 8,419 |
| Change in trade payables | -34,413 | 2,159 | 15,565 |
| Change in contract liabilities | 88,673 | 73,976 | -10,377 |
| Change in other liabilities | 1,239 | 7,896 | -1,411 |
| Operating cash flow | 96,119 | 83,831 | 145,027 |
| Cash outflow for capital expenditure for intangible assets | -11,856 | -11,581 | -50,560 |
| Cash inflow from disposals of property, plant and equipment | 171 | 63 | 349 |
| Cash outflow for capital expenditure for property, plant and equipment | -5,931 | -7,704 | -25,847 |
| Net cash outflow for company acquisitions (less acquired cash and cash equivalents and prepayments in previous periods) | -21,866 | -3,517 | -57,881 |
| Cash outflow for acquisitions from prior periods | -2,000 | 0 | -6,887 |
| Cash inflow from the disposal of subsidiaries and business units | 0 | 0 | 43 |
| Cash outflow for capital expenditures for joint ventures and other equity investments | 0 | -600 | -4,631 |
| Cash flow from investing activities | -41,482 | -23,339 | -145,414 |
| Buyback of treasury shares | 0 | -9,109 | -9,109 |
| Dividend paid | 0 | 0 | -26,117 |
| Capital paid to non-controlling interests | 0 | 0 | -175 |
| Acquisition of additional shares from non-controlling interests | 0 | -17 | -17 |
| Downpayment of lease liabilities | -6,262 | -5,626 | -25,530 |
| Cash inflow from borrowing of loans | 0 | 170,455 | 340,000 |
| Cash outflow from the repayment of loans | -72,396 | -193,405 | -295,411 |
| Cash flow from financing activities | -78,658 | -37,702 | -16,359 |
| Cash and cash equivalents at the beginning of the period | 90,517 | 107,343 | 107,343 |
| Change in cash and cash equivalents | -24,021 | 22,790 | -16,746 |
| Changes due to exchange rate fluctuations | -887 | 1,229 | -80 |
| Cash and cash equivalents at the end of the period | 65,609 | 131,362 | 90,517 |
| Interest paid | 7,033 | 2,092 | 6,157 |
| Interest received | 111 | 170 | 687 |
| Income taxes paid | 10,501 | 10,269 | 39,034 |

* Change in derivative financial instruments previously reported under changes in other receivables

Segment reporting

as of March 31, 2023

| | Segment AIS Ambulatory Information Systems | | | Segment HIS Hospital Information Systems | | | Segment CHS Consumer and Health Management Information Systems | | | Segment PCS Pharmacy Information Systems | | |
|---|---|-------------------|-------------------|---|-------------------|-------------------|---|-------------------|-------------------|---|-------------------|-------------------|
| | 2023 | 2022* | 2022* | 2023 | 2022 | 2022 | 2023 | 2022* | 2022* | 2023 | 2022 | 2022 |
| kEUR | 01.01 - 31.03. | 01.01 - 31.03. | 01.01 - 31.12. | 01.01 - 31.03. | 01.01 - 31.03. | 01.01 - 31.12. | 01.01 - 31.03. | 01.01 - 31.03. | 01.01 - 31.12. | 01.01 - 31.03. | 01.01 - 31.03. | 01.01 - 31.12. |
| Revenues to third parties | 124,827 | 119,671 | 502,287 | 73,125 | 66,594 | 277,217 | 57,880 | 35,450 | 219,594 | 35,011 | 29,933 | 130,547 |
| thereof Software license | 12,037 | 10,995 | 45,756 | 7,028 | 7,454 | 29,910 | 380 | 290 | 1,044 | 1,252 | 923 | 5,685 |
| thereof Hardware | 4,566 | 5,030 | 19,612 | 1,446 | 2,110 | 9,583 | 13,862 | 4,625 | 53,327 | 6,443 | 5,217 | 27,484 |
| thereof Professional Services | 7,404 | 8,021 | 41,409 | 13,514 | 10,085 | 47,358 | 6,938 | 2,905 | 22,897 | 3,737 | 2,711 | 12,228 |
| thereof Software Maintenance & hotline | 70,343 | 68,929 | 278,491 | 37,676 | 34,612 | 140,137 | 4,934 | 3,436 | 14,096 | 11,531 | 9,936 | 42,185 |
| thereof Other recurring revenues | 28,099 | 24,704 | 107,206 | 13,435 | 12,191 | 49,795 | 21,563 | 13,330 | 56,180 | 11,603 | 10,967 | 41,787 |
| thereof Adverting, eDetailing and Data | 145 | 129 | 682 | 0 | 0 | 0 | 9,596 | 10,383 | 69,039 | 196 | 136 | 490 |
| thereof Other revenues | 2,233 | 1,863 | 9,131 | 26 | 142 | 434 | 607 | 480 | 3,011 | 249 | 43 | 688 |
| Point in time of revenue recognition | | | | | | | | | | | | |
| at a specific point in time | 7,755 | 7,734 | 35,858 | 2,989 | 3,425 | 14,880 | 14,506 | 5,136 | 56,463 | 7,089 | 5,639 | 29,812 |
| over a period of time | 117,072 | 111,937 | 466,429 | 70,137 | 63,170 | 262,337 | 43,374 | 30,314 | 163,131 | 27,922 | 24,294 | 100,735 |
| | 124,827 | 119,671 | 502,287 | 73,126 | 66,595 | 277,217 | 57,880 | 35,450 | 219,594 | 35,011 | 29,933 | 130,547 |
| thereof recurring revenues | 98,442 | 93,634 | 385,697 | 51,111 | 46,803 | 189,932 | 26,497 | 16,766 | 70,276 | 23,134 | 20,903 | 83,972 |
| Revenues between segments | 20,600 | 10,536 | 84,009 | 1,403 | 1,105 | 5,347 | 12,392 | 3,421 | 47,089 | 1,111 | 815 | 4,160 |
| Segment Revenues | 145,427 | 130,208 | 586,295 | 74,529 | 67,699 | 282,564 | 70,272 | 38,871 | 266,683 | 36,122 | 30,748 | 134,707 |
| Capitalized inhouse services | 1,871 | 3,417 | 11,322 | 4,211 | 4,100 | 18,491 | 2,560 | 2,151 | 10,791 | 1,496 | 1,203 | 4,216 |
| Other income | 972 | 1,159 | 11,349 | 1,014 | 958 | 6,197 | 216 | 499 | 1,254 | 339 | 307 | 2,823 |
| Expenses for goods and services purchased | -35,162 | -25,931 | -145,521 | -11,371 | -11,225 | -48,077 | -36,268 | -12,597 | -133,798 | -9,268 | -7,401 | -35,242 |
| Personnel costs | -55,197 | -55,535 | -223,641 | -41,431 | -40,207 | -161,768 | -15,273 | -11,983 | -58,196 | -11,624 | -12,012 | -46,375 |
| Other expenses | -28,474 | -27,276 | -115,282 | -23,450 | -16,384 | -72,927 | -7,655 | -8,566 | -38,124 | -5,122 | -5,213 | -20,776 |
| EBITDA | 29,437 | 26,042 | 124,522 | 3,502 | 4,940 | 24,480 | 13,852 | 8,375 | 48,610 | 11,943 | 7,632 | 39,353 |
| in % of revenues | 23.6% | 21.8% | 24.8% | 4.8% | 7.4% | 8.8% | 23.9% | 23.6% | 22.1% | 34.1% | 25.5% | 30.1% |
| Depreciation of property, plant and equipment and right of use assets | | | | | | | | | | | | |
| Amortization of intangible assets | | | | | | | | | | | | |
| EBIT | | | | | | | | | | | | |
| Result from companies accounted for using the equity method | | | | | | | | | | | | |
| Financial income | | | | | | | | | | | | |
| Financial expenses | | | | | | | | | | | | |
| Net impairment losses on financial assets | | | | | | | | | | | | |
| EBT | | | | | | | | | | | | |
| Income taxes for the period | | | | | | | | | | | | |
| Consolidated net income for the period | | | | | | | | | | | | |
| in % of revenues | | | | | | | | | | | | |

* In 2023, some minor profit centers were reallocated between the AIS and CHS segments, therefore the prior year figures have been updated based on the current structure

Segment reporting

as of March 31, 2023

| | All other segments | | | Sum Segments | | | Consolidation | | | CGM Group | | |
|---|--------------------|----------------|----------------|----------------|----------------|------------------|----------------|----------------|-----------------|----------------|----------------|------------------|
| | 2023 | 2022 | 2022 | 2023 | 2022* | 2022* | 2023 | 2022* | 2022* | 2023 | 2022 | 2022 |
| kEUR | 01.01 - 31.03. | 01.01 - 31.03. | 01.01 - 31.12. | 01.01 - 31.03. | 01.01 - 31.03. | 01.01 - 31.12. | 01.01 - 31.03. | 01.01 - 31.03. | 01.01 - 31.12. | 01.01 - 31.03. | 01.01 - 31.03. | 01.01 - 31.12. |
| Revenues to third parties | 0 | 0 | 94 | 290,843 | 251,649 | 1,129,739 | 0 | 0 | 0 | 290,843 | 251,649 | 1,129,739 |
| thereof Software license | 0 | 0 | 0 | 20,697 | 19,662 | 82,395 | 0 | 0 | 0 | 20,697 | 19,662 | 82,395 |
| thereof Hardware | 0 | 0 | 0 | 26,317 | 16,982 | 110,006 | 0 | 0 | 0 | 26,317 | 16,983 | 110,006 |
| thereof Professional Services | 0 | 0 | 94 | 31,593 | 23,722 | 123,986 | 0 | 0 | 0 | 31,593 | 23,723 | 123,986 |
| thereof Software Maintenance & hotline | 0 | 0 | 0 | 124,484 | 116,913 | 474,909 | 0 | 0 | 0 | 124,484 | 116,914 | 474,909 |
| thereof Other recurring revenues | 0 | 0 | 0 | 74,700 | 61,192 | 254,968 | 0 | 0 | 0 | 74,700 | 61,192 | 254,968 |
| thereof Adverting, eDetailing and Data | 0 | 0 | 0 | 9,937 | 10,648 | 70,211 | 0 | 0 | 0 | 9,937 | 10,648 | 70,211 |
| thereof Other revenues | 0 | 0 | 0 | 3,115 | 2,528 | 13,264 | 0 | 0 | 0 | 3,115 | 2,528 | 13,264 |
| Point in time of revenue recognition | | | | | | | | | | | | |
| at a specific point in time | 0 | 0 | 0 | 32,339 | 21,934 | 137,013 | 0 | 0 | 0 | 32,339 | 21,934 | 137,013 |
| over a period of time | 0 | 0 | 94 | 258,505 | 229,715 | 992,726 | 0 | 0 | 0 | 258,505 | 229,715 | 992,726 |
| | 0 | 0 | 94 | 290,844 | 251,649 | 1,129,739 | 0 | 0 | 0 | 290,844 | 251,649 | 1,129,739 |
| thereof recurring revenues | 0 | 0 | 0 | 199,184 | 178,106 | 729,877 | 0 | 0 | 0 | 199,184 | 178,106 | 729,877 |
| Revenues between segments | 4,430 | 3,982 | 10,247 | 39,936 | 19,859 | 150,852 | -39,937 | -19,859 | -150,851 | -1 | 0 | 0 |
| Segment Revenues | 4,430 | 3,982 | 10,341 | 330,780 | 271,508 | 1,280,590 | -39,937 | -19,859 | -150,851 | 290,843 | 251,649 | 1,129,739 |
| Capitalized inhouse services | 437 | 0 | 0 | 10,575 | 10,872 | 44,820 | 0 | 0 | 0 | 10,575 | 10,872 | 44,820 |
| Other income | 21,853 | 25,652 | 96,853 | 24,394 | 28,574 | 118,476 | -23,120 | -27,460 | -99,080 | 1,274 | 1,115 | 19,396 |
| Expenses for goods and services purchased | -2,336 | -1,969 | -3,172 | -94,405 | -59,123 | -365,810 | 39,750 | 19,261 | 149,413 | -54,655 | -39,862 | -216,397 |
| Personnel costs | -12,157 | -13,982 | -57,572 | -135,682 | -133,719 | -547,552 | 132 | 608 | 848 | -135,550 | -133,111 | -546,704 |
| Other expenses | -12,101 | -13,928 | -67,020 | -76,802 | -71,368 | -314,129 | 23,014 | 27,287 | 99,625 | -53,788 | -44,082 | -214,504 |
| EBITDA | 126 | -245 | -20,570 | 58,860 | 46,744 | 216,395 | -161 | -163 | -45 | 58,699 | 46,581 | 216,350 |
| in % of revenues | | | | 20.2% | 18.6% | 19.2% | | | | 20.2% | 18.5% | 19.2% |
| Depreciation of property, plant and equipment and right of use assets | | | | | | | | | | -9,932 | -9,660 | -42,770 |
| Amortization of intangible assets | | | | | | | | | | -16,384 | -17,556 | -69,551 |
| EBIT | | | | | | | | | | 32,383 | 19,365 | 104,029 |
| Result from companies accounted for using the equity method | | | | | | | | | | 0 | 0 | -99 |
| Financial income | | | | | | | | | | 252 | 10,150 | 22,719 |
| Financial expenses | | | | | | | | | | -11,751 | -3,255 | -14,584 |
| Net impairment losses on financial assets | | | | | | | | | | 0 | 0 | -5,250 |
| EBT | | | | | | | | | | 20,884 | 26,260 | 106,815 |
| Taxes on income for the period | | | | | | | | | | -6,393 | -8,018 | -32,699 |
| Consolidated net income for the period | | | | | | | | | | 14,491 | 18,241 | 74,116 |
| in % of revenues | | | | | | | | | | 5.0% | 7.2% | 6.6% |

* In 2023, some minor profit centers were reallocated between the AIS and CHS segments, therefore the prior year figures have been updated based on the current structure

ADDITIONAL INFORMATION

Financial calendar

| Date | Event |
|-------------------|-----------------------------|
| May 17, 2023 | Annual General Meeting |
| August 10, 2023 | Interim Report Q2 2023 |
| September 7, 2023 | Capital Markets Day |
| November 9, 2023 | Quarterly Statement Q3 2023 |

Contact information

CompuGroup Medical SE & Co. KGaA

Investor Relations

Maria Trost 21

56070 Koblenz

E-Mail: investor@cgm.com

www.cgm.com

Management Responsibility Statement

To the best of our knowledge and in accordance with the applicable accounting principles for interim financial reporting, the consolidated interim financial statements give a true and fair view of the net assets, financial position, and results of operations of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group over the remainder of the financial year.

Koblenz, May 10, 2023

CompuGroup Medical SE & Co. KGaA
Represented by the Managing Directors
of CompuGroup Medical Management SE



Michael Rauch




Angela Mazza Teufer



Emanuele Mugnani



Dr. Eckart Pech



Hannes Reichl



CompuGroup Medical SE & Co. KGaA

Maria Trost 21
56070 Koblenz
Germany

www.cgm.com